Kazia Therapeutics Ltd ADR (KZIA)

Currency in USD
13.8000
-0.2800(-1.99%)
Closed·
13.77000.0000(0.00%)
·
KZIA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.770014.3300
52 wk Range
4.860017.4000
Key Statistics
Prev. Close
14.08
Open
14.13
Day's Range
13.77-14.33
52 wk Range
4.86-17.4
Volume
169.54K
Average Volume (3m)
219.03K
1-Year Change
52.4862%
Book Value / Share
2.74
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KZIA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
26.0064
Upside
+88.45%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Kazia Therapeutics Ltd ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 26.0064
(+88.45% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Lake Street
Buy32.00+131.88%-New CoverageJun 11, 2026
Laidlaw
Buy25.00+81.16%-New CoverageApr 15, 2026
H.C. Wainwright
Buy18.00+30.43%-MaintainJan 28, 2026
H.C. Wainwright
Buy18.00+30.43%13.00MaintainDec 12, 2025
H.C. Wainwright
Buy13.00-5.80%-MaintainOct 28, 2025

Earnings

Latest Release
Nov 07, 2025
EPS / Forecast
-7.64 / -221.00
Revenue / Forecast
1.81M / --
EPS Revisions
Last 90 days

KZIA Income Statement

Compare KZIA to Peers and Sector

Metrics to compare
KZIA
Peers
Sector
Relationship
P/E Ratio
−10.0x9.1x−0.5x
PEG Ratio
−0.130.050.00
Price/Book
4.9x1.0x2.6x
Price / LTM Sales
119.9x1.7x3.0x
Upside (Analyst Target)
96.9%344.0%58.6%
Fair Value Upside
Unlock0.5%10.2%Unlock

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
220.93K1.93%3.15M
Other Institutional Investors
2.95M25.84%42.17M
Public Companies & Retail Investors
8.25M72.23%117.86M
Total
11.43M100.00%163.18M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Exemplar Growth and Income Fund1.93%220,7313,108
Fidelity Concord Street Trust - Fidelity Nasdaq Composite Index Fund0.00%1953

People Also Watch

117.24
KLIC
+1.56%
84.39
MXL
-4.92%
320.46
VICR
-0.60%
9.3750
LWLG
-6.99%
282.68
SIMO
+2.27%

FAQ

What Is the Kazia Therapeutics ADR (KZIA) Stock Price Today?

The Kazia Therapeutics ADR stock price today is 13.8000 USD.

What Stock Exchange Does Kazia Therapeutics ADR Trade On?

Kazia Therapeutics ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Kazia Therapeutics ADR?

The stock symbol for Kazia Therapeutics ADR is "KZIA."

What Is the Kazia Therapeutics ADR Market Cap?

As of today, Kazia Therapeutics ADR market cap is 160.8900M USD.

What Is Kazia Therapeutics ADR's Earnings Per Share (TTM)?

The Kazia Therapeutics ADR EPS (TTM) is -10.2231.

From a Technical Analysis Perspective, Is KZIA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Kazia Therapeutics ADR Stock Split?

Kazia Therapeutics ADR has split 4 times.

How Many Employees Does Kazia Therapeutics ADR Have?

Kazia Therapeutics ADR has 6 employees.

What is the current trading status of Kazia Therapeutics ADR (KZIA)?

As of Jun 16, 2026, Kazia Therapeutics ADR (KZIA) is trading at a price of 13.8000 USD, with a previous close of 14.0800 USD. The stock has fluctuated within a day range of 13.7700 USD to 14.3300 USD, while its 52-week range spans from 4.8600 USD to 17.4000 USD.

What Is Kazia Therapeutics ADR (KZIA) Price Target According to Analysts?

The average 12-month price target for Kazia Therapeutics ADR is 26.0064 USD, with a high estimate of 32.13422735 USD and a low estimate of 17.65922947 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +88.45% Upside potential.

What Is the KZIA Premarket Price?

KZIA's last pre-market stock price is 14.1200 USD. The pre-market share volume is 190.0000, and the stock has decreased by 0.0400, or 0.2800%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.